Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 24% of the time (231 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-03-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerprostategreater thanor equalequal to
  Phrases that lowered it: participantssubjectsthis trialkgsubject
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past termination rate: 9.9% (raises risk) · Sponsor's track record
• Maximum age: 100 (lowers risk) · Who can join
• Primary purpose: diagnostic (lowers risk) · Design
• Drug's FAERS reports with a death: 10.9% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 286 (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 464 (lowers risk) · Sponsor's track record
• Sponsor type: government (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 72.4% (lowers risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 7001 (lowers risk) · Drug's FDA history
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers NCT02141490 · started 2014 · scored riskier than 95% of active trials completed
• Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients NCT04261777 · started 2020 · scored riskier than 22% of active trials terminated
• Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer NCT00924313 · started 2008 · scored riskier than 47% of active trials completed
• Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer NCT01867424 · started 2013 · scored riskier than 98% of active trials completed
• Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer NCT02430480 · started 2015 · scored riskier than 74% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.